All Press Releases for January 09, 2023

Dr. Josefino B. Tunac has been Inducted into the Prestigious Marquis Who's Who Biographical Registry

Dr. Tunac is recognized for his expertise in leading biotechnology research

Dr. Tunac plans to continue to develop his novel 'Burglar-proofing' paradigm to cure a variety of diseases by repairing and maintaining the integrity of a healthy cell.

    OXFORD, MI, January 09, 2023 /24-7PressRelease/ -- Dr. Josefino B. Tunac has been included in Marquis Who's Who. As in all Marquis Who's Who biographical volumes, individuals profiled are selected on the basis of current reference value. Factors such as position, noteworthy accomplishments, visibility, and prominence in a field are all taken into account during the selection process.

Leveraging more than four decades of excellence in biotechnology research, Dr. Tunac has earned distinction as a leader of Arterez Inc. In this capacity, he is the president and chairman for the company, focusing his efforts on leading the development of multifactorial therapies and diagnostics for use in diseases. Dr. Tunac's concept is that diseases start when foreign objects disrupt the protective shield of the cell. Cells are made of biomolecules, which are bonded by electrons and the integrity of the bond maintains a healthy cell. Electron-stealing chemicals oxidize this bond and create foreign molecules eventually activating the second defense, which involves the immune system and a multifactorial cascade of disruption. Targeting a single component in the cascade only offers a putative or band-aid treatment. Their lead therapeutic is presently Embotricin, a multicomponent oral drug against cardiovascular disease for use to prevent and reverse the buildup of arterial plaque.

Prior to his current role, Dr. Tunac began his career as a senior scientist with Merck and then served as the director of antibiotics and chemotherapy for Warner-Lambert and Parke-Davis, which was later acquired by Pfizer. He then founded Fermical, Inc., a biotechnology research company, and Farmaceutix, LLC, which develops drugs for treating chronic diseases in humans. Over the course of his career, he has secured 30 patents for his work and one of his works, Avermectin®, was honored with a Nobel Prize in Medicine in 2015. He discovered his first drug (Hydroheptin) at the Waksman Institute and at Merck he was instrumental in the discovery and development of multi-billion dollar drugs, including Ivomec® Heartgard® and Primaxin®. He invented the Tunair™ flask, now used worldwide in the culturing of microorganisms. His latest patent "Biomarker panel targeted to diseases due to multifactorial ontology of glycocalyx disruption" was published on December 8, 2022. Dr. Tunac was also named Entrepreneur of the Year by the Metropolitan Center for High Technology in Detroit, Michigan.

Prior to embarking on his professional journey, Dr. Tunac earned a Bachelor of Science from the University of the Philippines. He then completed graduate studies at South Dakota State University and Penn State University, attaining his doctorate at Rutgers University.

Within the coming years, Dr. Tunac plans to continue to develop his novel 'Burglar-proofing' paradigm to cure a variety of diseases by repairing and maintaining the integrity of a healthy cell. The upstream cause of pathologies is the physical breach of the glycocalyx, a protective coating of cells, by extraneous agents (xeno), resulting in a sequela of cell damages (plexic) that is manifested downstream in the form of diseases, which Dr. Tunac describes as "xenoplexic diseases." Glycocalyx disruption sheds debris in the bloodstream and the unique pattern is being exploited by Dr. Tunac as a basis for 'diagnostic fingerprint' for diseases, the "Glycocalyx Detritus Fingerprint." He originally joined biotechnology research after learning about the discovery of penicillin while living in the Philippines. He was fascinated about how such a small drug could make a whole body healthy after experiencing disease and committed himself to following his passion for finding other such cures.

About Marquis Who's Who®
Since 1899, when A. N. Marquis printed the First Edition of Who's Who in America®, Marquis Who's Who® has chronicled the lives of the most accomplished individuals and innovators from every significant field of endeavor, including politics, business, medicine, law, education, art, religion and entertainment. Today, Who's Who in America® remains an essential biographical source for thousands of researchers, journalists, librarians and executive search firms around the world. Marquis® now publishes many Who's Who titles, including Who's Who in America®, Who's Who in the World®, Who's Who in American Law®, Who's Who in Medicine and Healthcare®, Who's Who in Science and Engineering®, and Who's Who in Asia®. Marquis® publications may be visited at the official Marquis Who's Who® website at

# # #

Contact Information

-- --
Marquis Who's Who Ventures LLC
Uniondale, NY
Voice: 844-394-6946
E-Mail: Email Us Here
Website: Visit Our Website
Follow Us: